…the number of individuals affected by Dementia, Parkinson’s disease and ALS who require help with their symptoms. It is imperative to increase disease awareness and availability of treatment options to…
Content Section: News Posts
…“After re-examining its initial opinion, the EMA… has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer’s disease,” the European Medicines…
Content Section: News Posts
…to 57% for dementia-focused groups and 55% for those focused on neuromuscular conditions. Only 25% of multiple sclerosis groups reported similar concerns. Neurology-Specific Challenges The primary needs identified by neurology…
Content Section: News Posts
…for both dementia and Parkinson’s disease. Hearing aid use significantly reduces Parkinson’s disease incidence, but further studies are needed to assess adherence and other influencing factors. The study’s generalisability is…
Content Section: News Posts
…reduced another gene, Mapt, which encodes the tau protein and is a target for the treatment of Alzheimer’s disease and other dementias. This development has the potential to advance treatments for…
Content Section: News Posts
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.
